Bortezomib consolidation post ‐ASCT as frontline therapy for multiple myeloma deepens disease response and MRD‐negative rate whilst maintaining QOL and response to re‐treatment at relapse
British Journal of Haematology, EarlyView. (Source: British Journal of Haematology)
Source: British Journal of Haematology - November 20, 2018 Category: Hematology Authors: Oliver C. Cohen,
Nicholas Counsell,
Neil Rabin,
Rakesh Popat,
Roger G. Owen,
Bilyana Popova,
Oliver Schofield,
Laura Clifton ‐Hadley,
Janet Lyons‐Lewis,
Andy Rawstron,
Christopher Spence,
Ruth M. Tute,
Derralynn Hughes,
Sally Moore,
Paul Tags: Correspondence Source Type: research
Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenstr öm macroglobulinaemia on ibrutinib
British Journal of Haematology, EarlyView. (Source: British Journal of Haematology)
Source: British Journal of Haematology - November 20, 2018 Category: Hematology Authors: Matthew P. Cheng,
Amanda E. Kusztos,
Joshua N. Gustine,
Scott L. Dryden ‐Peterson,
Toni E. Dubeau,
Ann E. Woolley,
Sarah P. Hammond,
Lindsey R. Baden,
Steven P. Treon,
Jorge J. Castillo,
Nicolas C. Issa Tags: Correspondence Source Type: research
Spontaneous remission in a Diamond ‐Blackfan anaemia patient due to a revertant uniparental disomy ablating a de novo RPS19 mutation
British Journal of Haematology, EarlyView. (Source: British Journal of Haematology)
Source: British Journal of Haematology - November 20, 2018 Category: Hematology Authors: Emanuela Garelli,
Paola Quarello,
Elisa Giorgio,
Adriana Carando,
Elisa Menegatti,
Cecilia Mancini,
Eleonora Di Gregorio,
Nicoletta Crescenzio,
Orazio Palumbo,
Massimo Carella,
Paola Dimartino,
Tommaso Pippucci,
Irma Dianzani,
Ugo Ramenghi,
Tags: Correspondence Source Type: research
Current considerations in AYA Hodgkin lymphoma
SummaryHodgkin lymphoma (HL) commonly occurs in adolescents and young adults (AYA), defined by the National Cancer Institute as people diagnosed with cancer between the ages of 15 and 39 years. Despite therapeutic advances, the AYA population has derived less incremental benefit compared to both paediatric and adult counterparts. Although the exact aetiology is unclear, contributing factors probably include differences in disease biology, delayed diagnosis, decreased participation in clinical trials and treatment adherence secondary to complex social factors. As such, while HL remains highly curable, there is not a clear...
Source: British Journal of Haematology - November 20, 2018 Category: Hematology Authors: Jennifer L. Crombie,
Ann S. LaCasce Tags: Review Source Type: research
Detailed molecular analysis and evaluation of prognosis in cases with high grade B ‐cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
British Journal of Haematology, EarlyView. (Source: British Journal of Haematology)
Source: British Journal of Haematology - November 20, 2018 Category: Hematology Authors: Anna Stengel,
Wolfgang Kern,
Manja Meggendorfer,
Torsten Haferlach,
Claudia Haferlach Tags: Correspondence Source Type: research
A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia
British Journal of Haematology, EarlyView. (Source: British Journal of Haematology)
Source: British Journal of Haematology - November 19, 2018 Category: Hematology Authors: Hartmut D öhner,
Carsten Müller‐Tidow,
Michael Lübbert,
Walter Fiedler,
Alwin Krämer,
Jörg Westermann,
Gesine Bug,
Richard F. Schlenk,
Utz Krug,
Rainer‐Georg Goeldner,
James Hilbert,
Tillmann Taube,
Oliver G. Ottmann Tags: Correspondence Source Type: research
Ventricular global longitudinal strain is altered in children with sickle cell disease
SummaryCardiac disease is the primary cause of death in sickle cell disease (SCD). Right and left ventricular global longitudinal strain (RVGLS, LVGLS) are early markers of systolic dysfunction but are not well investigated among children with SCD. One hundred and forty ‐three patients with HbSS or HbSβ0‐thalassaemia (median age 11 years, range 5–19 years) and 71 controls matched for age and sex were compared. RVGLS and LVGLS were measured and compared with conventional measures of echocardiography and markers of haemolysis and inflammation. RVGLS was higher in children with SCD than in contr ols (−25·72% ± ...
Source: British Journal of Haematology - November 19, 2018 Category: Hematology Authors: Nicholas S. Whipple,
Ronak J. Naik,
Guolian Kang,
Joseph Moen,
Sarala D. Govindaswamy,
James A. Fowler,
Jolanta Dowdy,
Rhiannon Penkert,
Vijaya M. Joshi,
Jane S. Hankins Tags: Research Paper Source Type: research
Insulin ‐like growth factor levels and chronic lymphocytic leukaemia: results from the MCC‐Spain and EpiLymph‐Spain studies
British Journal of Haematology, EarlyView. (Source: British Journal of Haematology)
Source: British Journal of Haematology - November 19, 2018 Category: Hematology Authors: Delphine Casabonne,
Yolanda Benavente,
Laura Costas,
Claudia Robles,
Eva Gonzalez ‐Barca,
Esmeralda Banda,
Esther Alonso,
Marta Aymerich,
Elías Campo,
Rafael Marcos‐Gragera,
Adonina Tardón,
Rocío Olmedo‐Requena,
Eva Gimeno,
Alba Mart Tags: Correspondence Source Type: research
Venous thromboembolism in multiple myeloma – choice of prophylaxis, role of direct oral anticoagulants and special considerations
SummaryMultiple myeloma is associated with a significant risk of venous thromboembolism (VTE), causing substantial levels of morbidity and mortality. The thrombogenicity of myeloma is multifactorial, with disease ‐ and treatment‐related factors playing important roles. Immunomodulatory drugs (IMiDs) and high‐dose dexamethasone, in particular, are known to enhance the thrombotic potential of myeloma. For this reason, assessment of the VTE risk has long been advocated prior to treatment initiation in pat ients with myeloma requiring IMiD‐based regimens. However, despite routine use of thromboprophylaxis, these patien...
Source: British Journal of Haematology - November 18, 2018 Category: Hematology Authors: Dawn Swan,
Alberto Rocci,
Charlotte Bradbury,
Jecko Thachil Tags: Review Source Type: research
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis
British Journal of Haematology, EarlyView. (Source: British Journal of Haematology)
Source: British Journal of Haematology - November 18, 2018 Category: Hematology Authors: Martina Barone,
Francesca Ricci,
Daria Sollazzo,
Emanuela Ottaviani,
Marco Romano,
Giuseppe Auteri,
Daniela Bartoletti,
Maria L. B. Reggiani,
Nicola Vianelli,
Pier L. Tazzari,
Michele Cavo,
Dorian Forte,
Francesca Palandri,
Lucia Catani Tags: Correspondence Source Type: research
Bioimpedance vector analysis for the detection of extracellular volume overload and sarcopenia in systemic AL amyloidosis
British Journal of Haematology, EarlyView. (Source: British Journal of Haematology)
Source: British Journal of Haematology - November 18, 2018 Category: Hematology Authors: Tamer Rezk,
Andrew Davenport,
Jaslyn J. Gan,
Helen J. Lachmann,
Marianna Fontana,
Ana Martinez ‐Naharro,
Sajitha Sachchithanantham,
Christianne Guillotte,
Shameem Mahmood,
Aviva Petrie,
Carol J. Whelan,
Jennifer H. Pinney,
Darren Foard,
Thi Tags: Correspondence Source Type: research
Genetic predisposition to PEG ‐asparaginase hypersensitivity in children treated according to NOPHO ALL2008
This study associated variants inCNOT3 and in the human leucocyte antigen (HLA) region with PEG ‐asparaginase hypersensitivity, suggesting that not only genetic variations in the HLA region, but also regulation of these genes are of importance in the biology of this toxicity. Furthermore, our study emphasizes the importance of using asparaginase enzyme activity measurements to identify PEG‐ asparaginase hypersensitivity. (Source: British Journal of Haematology)
Source: British Journal of Haematology - November 18, 2018 Category: Hematology Authors: Sofie G. H øjfeldt,
Benjamin O. Wolthers,
Morten Tulstrup,
Jonas Abrahamsson,
Ramneek Gupta,
Arja Harila‐Saari,
Mats Heyman,
Louise T. Henriksen,
Òlafur G. Jónsson,
Päivi M. Lähteenmäki,
Bendik Lund,
Kaie Pruunsild,
Goda Vaitkeviciene, Tags: Research Paper Source Type: research
Saposin C is a frequent target of paraproteins in Gaucher disease ‐associated MGUS/multiple myeloma
SummaryPatients with Gaucher disease (GD) have an increased risk of monoclonal gammopathies for which antigenic targets might play a role in their pathogenesis. Here we report the identification of saposin C (sapC) as high ‐titre (1:1 000 000) target structure of 7/16 GD‐associated paraproteins. Anti‐sapC immunoglobulin (Ig) showed identity with the paraprotein Ig type and subclass in each patient that showed anti‐sapC immunoreactivity. Absorption and depletion studies completely removed the paraprotein from the sera of GD patients. No immunoreactivity against sapC was detected in healthy donors and in other plas...
Source: British Journal of Haematology - November 18, 2018 Category: Hematology Authors: Klaus ‐Dieter Preuss,
Carla E. M. Hollak,
Natalie Fadle,
Marinus Oers,
Evi Regitz,
Michael Pfreundschuh Tags: Research Paper Source Type: research
Mature outcomes and prognostic indices in diffuse large B ‐cell lymphoma in Malawi: a prospective cohort
We report mature data from one of the first prospective SSA cohorts. Patients aged ≥18 years with DLBCL were enrolled in Malawi 2013–2017. Participants were treated with CHOP (cyclophosphamide, doxorubicin, vincristine , prednisone) chemotherapy and concurrent antiretroviral therapy (ART) if positive for human immunodeficiency virus (HIV+). Eighty‐six participants (mean age 47 years, standard deviation 13) were enrolled: 54 (63%) were male and 51 (59%) were HIV+, of whom 34 (67%) were on ART at DLBCL diagnosis. Median CD4 count was 0·113 cells × 109/l (interquartile range [IQR] 0 ·062–0·227) and 25 (49%) ha...
Source: British Journal of Haematology - November 18, 2018 Category: Hematology Authors: Matthew S. Painschab,
Edwards Kasonkanji,
Takondwa Zuze,
Bongani Kaimila,
Tamiwe Tomoka,
Richard Nyasosela,
Ruth Nyirenda,
Bal M. Dhungel,
Maurice Mulenga,
Maria Chikasema,
Blessings Tewete,
Asekanadziwa Mtangwanika,
Sarah Chiyoyola,
Wilberfo Tags: Research Paper Source Type: research
Ticagrelor does not impact patient ‐reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb study
SummaryTicagrelor is an antiplatelet agent for adults with coronary artery disease. The inhibition of platelet activation may decrease the frequency of vaso ‐occlusion crisis (VOC) in sickle cell disease (SCD). The HESTIA2 study (NCT02482298) randomised 87 adults with SCD (aged 18–30 years) 1:1:1 to twice‐daily ticagrelor 10, 45 mg or placebo for 12 weeks. Numerical decreases from baseline in mean proportion of days with patient‐reported pain (primary endpoint) were seen in all three groups, as well as in pain intensity and analgesic use, with no significant differences between placebo and ticagrelor treatment g...
Source: British Journal of Haematology - November 16, 2018 Category: Hematology Authors: Julie Kanter,
Miguel R. Abboud,
Banu Kaya,
Videlis Nduba,
Carl Amilon,
Christer Gottfridsson,
Martin Rensfeldt,
Maria Leonsson ‐Zachrisson,
on behalf of the HESTIA2 study investigators Tags: Research Paper Source Type: research
